top of page

5 most promising Fintech startups

Jess Wilder

Mar 17, 2023

This is placeholder text. To change this content, double-click on the element and click Change Content.

This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more.


Your collection is already set up for you with fields and content. Add your own content or import it from a CSV file. Add fields for any type of content you want to display, such as rich text, images, and videos. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site.


texture_bg.jpg

SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform

ALISO VIEJO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced that 18-month data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated improvements in both visual acuity and intraocular pressure (IOP) outcomes, key objectives for long-term treatment of glaucoma or ocular hypertension. The data will be highlighted in a poster presentation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 25-28, 2025, in Los Angeles. (View full press release)

Spyglass Pharma Logo - Long - Black_edited.png

Tel: 949-284-6904

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Thanks for submitting!

SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer

© 2025 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

  • LinkedIn
bottom of page